Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer

No abstract is available for this paper.

• Publication year

  2018

• Venue

  International Journal of Colorectal Disease

• Publication date

  2018-06-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00384-018-3095-6PMID 29869121
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study

  2017cited by this paper
• Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

  2017cited by this paper
• Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

  2016cited by this paper
• Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials

  2016cited by this paper
• Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

  2016cited by this paper
• Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastases.

  2016cited by this paper
• Microbiota disbiosis is associated with colorectal cancer

  2015cited by this paper
• Variations in Metastasis Site by Primary Location in Colon Cancer

  2015cited by this paper
• Microbiota organization is a distinct feature of proximal colorectal cancers

  2014cited by this paper
• Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.

  2014cited by this paper
• BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer

  2014cited by this paper
• Fusobacterium in colonic flora and molecular features of colorectal carcinoma.

  2014cited by this paper
• Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.

  2014cited by this paper
• Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer

  2013cited by this paper
• Colorectal Cancers from Distinct Ancestral Populations Show Variations in BRAF Mutation Frequency

  2013cited by this paper
• Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.

  2013cited by this paper
• Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location

  2013cited by this paper
• BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.

  2013cited by this paper
• Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.

  2013cited by this paper
• Clinicopathological relevance of BRAF mutations in human cancer

  2013cited by this paper
• BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome

  2013cited by this paper
• BRAF mutation in sporadic colorectal cancer and Lynch syndrome

  2013cited by this paper
• Tumor adaptation and resistance to RAF inhibitors

  2013cited by this paper
• BRAF Mutations in Colorectal Cancer Are Associated With Distinct Clinical Characteristics and Worse Prognosis

  2012cited by this paper
• A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction

  2012cited by this paper
• BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon: An Aggressive Adenocarcinoma With Poor Survival, Mucinous Differentiation, and Adverse Morphologic Features

  2012cited by this paper
• Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation

  2011cited by this paper
• Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.

  2011cited by this paper
• BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

  2011cited by this paper
• KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.

  2011cited by this paper
• Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

  2011cited by this paper
• Comparison of 17,641 Patients With Right- and Left-Sided Colon Cancer: Differences in Epidemiology, Perioperative Course, Histology, and Survival

  2010cited by this paper
• Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

  2010cited by this paper
• The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status

  2010cited by this paper
• Role of the serrated pathway in colorectal cancer pathogenesis.

  2010cited by this paper
• Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosis

  2010cited by this paper
• Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer

  2010cited by this paper
• The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.

  2010cited by this paper
• KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

  2009cited by this paper
• Paneth cell differentiation in colonic epithelial neoplasms: evidence for the role of the Apc/beta-catenin/Tcf pathway.

  2009cited by this paper
• V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway

  2009cited by this paper
• Negative Serum Carcinoembryonic Antigen has Insufficient Accuracy for Excluding Recurrence from Patients with Dukes C Colorectal Cancer: Analysis with Likelihood Ratio and Posttest Probability in a Follow-Up Study

  2008cited by this paper
• Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.

  2008cited by this paper
• Comparison of Microsatellite Instability, CpG Island Methylation Phenotype, BRAF and KRAS Status in Serrated Polyps and Traditional Adenomas Indicates Separate Pathways to Distinct Colorectal Carcinoma End Points

  2006cited by this paper
• Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers.

  2005cited by this paper
• Hyperplastic Polyps, Serrated Adenomas, and the Serrated Polyp Neoplasia Pathway

  2004cited by this paper
• Mechanisms of regulating the Raf kinase family.

  2003cited by this paper
• Age and adjuvant chemotherapy use after surgery for stage III colon cancer.

  2001cited by this paper
• Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC

  1997cited by this paper
• A genetic model for colorectal tumorigenesis.

  1990cited by this paper

• Assessment of BRAF Mutations Status in 320 Moroccan Colorectal Cancer Patients and Its Correlation with Clinico-Pathological Characteristics: The Largest North African Case Series

  2025cites this paper
• Expert consensus on the optimal management of BRAFV600E ‐mutant metastatic colorectal cancer in the Asia‐Pacific region

  2024cites this paper
• Rectal pleomorphic giant cell carcinoma combined with BRAF (V600E) mutation: A case report and literature review.

  2024cites this paper
• Impact of perioperative prognostic nutritional index changes on the survival of patients with stage II/III colorectal cancer

  2024cites this paper
• KRAS and BRAF Mutation Rates and Survival Outcomes in Colorectal Cancer in an Ethnically Diverse Patient Cohort

  2023cites this paper
• DNA and RNA Alterations Associated with Colorectal Peritoneal Metastases: A Systematic Review

  2023influential citation
• Predictive Genetic Biomarkers for the Development of Peritoneal Metastases in Colorectal Cancer

  2023cites this paper
• The Effect of the Mucinous Component Presence on the Clinical Outcomes of Colorectal Cancer

  2022cites this paper
• Clinical Significance of Genetic Variants in Colon Cancer

  2022cites this paper
• Risk Factors for Synchronous Peritoneal Metastases in Colorectal Cancer: A Systematic Review and Meta-Analysis

  2022cites this paper
• Which patients are prone to suffer liver metastasis? A review of risk factors of metachronous liver metastasis of colorectal cancer

  2022cites this paper
• Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia

  2021cites this paper
• МЕТААНАЛИЗ ИССЛЕДОВАНИЙ ПО СРАВНЕНИЮ ЭФФЕКТИВНОСТИ РЕЖИМОВ FOLFOXIRI И FOLFOX ИЛИ FOLFIRI С ТАРГЕТНОЙ ТЕРАПИЕЙ ПРИ МЕТАСТАТИЧЕСКОМ РАКЕ ТОЛСТОЙ КИШКИ С МУТАЦИЕЙ В ГЕНЕ BRAF

  2020cites this paper
• Imaging predictors of BRAF mutation in colorectal cancer

  2020cites this paper
• Histologic features and genomic alterations of primary colorectal adenocarcinoma predict growth patterns of liver metastasis

  2019cites this paper